30 Technology enters into a strategic Licencing Agreement to develop new treatments for multi-drug resistant tuberculosis
London, UK, 22 February 2021.
Thirty Holdings Limited (“30 Technology”) is delighted to announce a multi-year research and development partnership to develop a new medicine to treat drug-resistant strains of tuberculosis (TB). This is the first of many development partnerships. 30 Technology is a clinical stage pharmaceutical company with a platform portfolio based on its proprietary multi-modal nitric oxide generating technology. Products are in development and in clinical trials to target multiple chronic respiratory diseases, bacterial and viral infections.
Commenting on the agreement, 30 Technology’s Executive Director, Justin Barnes said “we are delighted to have entered into our first external research and development agreement. During the past 2 years we have built a first-class in-house research capability and in collaboration with global TB experts demonstrated significant in-vitro efficacy against both hyper virulent drug-sensitive and multi-drug resistant strains of TB.”
Under the agreement 30 Technology receives £5m upfront funding and during the next two years will develop a proprietary inhaled nitric oxide generating respiratory product to target this highly resistant and damaging pathogen. The developed product will be advanced to clinical studies thereafter.
30 Technology is developing new medicines to improve the lives of patients suffering from serious and life-threatening medical conditions. Our corporate strategy is twofold; 1) develop wholly owned assets and 2) develop products with external partners for royalty streams.
The first internally developed and wholly owned break-through product, RESP301 has shown broad activity against a range of respiratory viruses, including influenza and rhinovirus and is being investigated in clinical studies.
- PREVENT: a multi-centre post-exposure RCT in 600 people to prevent transmission of COVID-19 in the community.
- NOCoV2: a multi-centre phase II/III RCT treating patients hospitalised with COVID-19.
- NOMAB: a phase II study to treat chronic infection with Mycobacterium abscessus in patients with cystic fibrosis.
- CORVIS: A multi-centre phase II study to treat viral exacerbations in 150 people with underlying lung conditions, such as COPD and bronchiectasis, in the community.
Commenting on the importance of Tuberculosis, 30 Technology’s Chief Medical Officer, Professor Chris Wood said “Antibiotic resistance is one of the biggest threats to global health and is unsurprisingly prevalent within TB. The opportunity to develop a cost-effective product to treat TB is vital and something we look forward to delivering.’
TB is the leading killer among diseases caused by an infectious agent worldwide and the leading killer of people with HIV infection Indeed, worldwide, TB remains one of the top 10 causes of death. Globally, 3.5% of new TB cases and 18% of previously treated cases had multidrug-resistant TB, highlighting the need for more sustainable methods of treatment (WHO, 2018). The transmission of drug resistant tuberculosis is a particular challenging in low resource settings where isolation of infectious patients is difficult and infection control systems are relatively weak. According to the WHO (2019), 20% of all patients diagnosed with active TB disease each year are infected with M. tuberculosis strains that are drug-resistant to various degrees: 10% are mono-resistant, and the other 10% are multi-drug resistant (MDR) or extensively drug resistant (XDR).
RESP301 is a NO-generating liquid designed to release NO in situ in the upper airways and deep in the alveolar spaces. RESP301 is an admixture solution of two precursor solutions mixed at point of care for immediate inhaled administration via a handheld nebuliser and has specific advantages in treating a range of respiratory viruses, including SARS-CoV-2. In laboratory testing, RESP301 has also demonstrated potent activity against various influenza virus strains, rhinovirus and coronavirus. It has also shown high in vitro activity against other respiratory pathogens, both viral and bacterial. The novel concept for RESP301 is that it will restore the levels of NO in the lungs with a dual action of both killing virus and bacteria and boosting the host response against these pathogenic microbes.
About 30 Technology
30 Technology is a privately owned biopharmaceutical company developing proprietary NO-generating technologies. The products that 30 Technology has developed have very broad application in many areas of medicine.
For further information, please contact: email@example.com
30 TECHNOLOGY is developing and defining new models of care to treat many serious medical conditions by enhancing the body’s healing and defence mechanisms.
30 TECHNOLOGY Therapeutic Nitric Oxide